Journal
JOURNAL OF HYPERTENSION
Volume 22, Issue 8, Pages 1571-1577Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.hjh.0000133718.86451.6a
Keywords
angiotensin subtype 1 receptor; angiotensin II; nitric oxide; valsartan; losartan
Categories
Funding
- NHLBI NIH HHS [K04-HL-03006, HL-57503] Funding Source: Medline
- NIDDK NIH HHS [DK-61400] Funding Source: Medline
Ask authors/readers for more resources
Objective Diabetes mellitus is associated with increased incidence of cardiovascular complications. Lack of nitric oxide production may exacerbate these complications. We hypothesized that diabetes decreases renal nitric oxide (NO) production, an effect that is reversed via inhibition of angiotensin subtype-1 receptor. Methods We monitored changes in renal interstitial fluid nitric oxide by a microdialysis technique in the renal cortex of conscious Sprague-Dawley rats. Rats (n = 8 each group) were given streptozotocin 30 mg/kg intravenously to induce diabetes. Changes in renal interstitial fluid angiotensin 11 and NO were evaluated at baseline before and over 12 weeks during the development of diabetes and at 4 and 8 h after oral administration of the angiotensin subytype-1 (AT,) receptor blockers, losartan (30 mg/kg) or valsartan (110 mg/kg). Results Renal interstitial fluid angiotensin 11 significantly increased after development of diabetes. In contrast, basal renal interstitial fluid nitric oxide decreased significantly over 12 weeks after development of diabetes. Both losartan and valsartan caused a further increase in renal angiotensin 11 levels. Some 4 h after administration, there was significantly greater increase in renal nitric oxide after administration of valsartan than of losartan. At 8 h post-treatment, only valsartan caused a significant increase in renal nitric oxide levels. Conclusion These results demonstrate that diabetes mellitus is associated with an increase in renal production of angiotensin 11, while renal production of nitric oxide is reduced. The decrease in renal NO is reversed by AT, receptor blockade.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available